Anktiva (N-803) for Stage IV Cancer
Also known as: N-803, ALT-803, Nogpendekin alfa inbakicept
The first IL-15 superagonist approved for cancer, Anktiva represents a new class of immunotherapy that activates NK cells and CD8+ T cells.
Mechanism of Action
N-803 is an IL-15/IL-15Rα-Fc fusion protein that trans-presents IL-15 to NK cells and CD8+ T cells. It drives proliferation of cytotoxic lymphocytes, enhances antibody-dependent cellular cytotoxicity (ADCC), reinvigorates exhausted T cells in the tumor microenvironment, and promotes memory T cell formation for durable immune response.
General mechanism: IL-15/IL-15Rα-Fc superagonist. NK cell and CD8+ T cell activation. ADCC enhancement. T cell memory formation.
Current Evidence
FDA-approved for BCG-unresponsive bladder cancer (2024). Phase II/III trials ongoing for NSCLC, pancreatic cancer, and other solid tumors. Combination with checkpoint inhibitors shows enhanced response rates. Synergy with ADCC-mediating antibodies demonstrated.
Clinical Status: FDA-approved for bladder cancer (2024). Multiple ongoing trials for solid tumors. Combination studies with pembrolizumab and other agents.
Safety Profile
Injection site reactions, fatigue, nausea. Cytokine release possible. Generally well-tolerated. Different safety profile from checkpoint inhibitors.
Key Research Questions
- What is the optimal combination of Anktiva with checkpoint inhibitors for solid tumors?
- Can NK cell expansion with Anktiva overcome immunosuppressive tumor microenvironments?
- Does Anktiva-enhanced ADCC improve response to therapeutic antibodies like trastuzumab?